Main sector:
Biotechnology - Therapeutics and Diagnostics
Subsectors:
Antibodies
Anti-infectives
Cell therapy
Nucleic acid drugs
Small molecules
Vaccines
Immunotherapy
Antibody-drug-conjugate
Indications:
Infectious and parasitic diseases / infectiology / parasitology
Neoplasms / cancer / oncology
Respiratory / pulmonology
Products
In development: 60
On the market: 1
Description:
BioNTech SE develops and commercializes immunotherapies to treat cancer and infectious diseases. The company's product BNT116 is an mRNA cancer immunotherapy candidate encoding a fixed set of six non-mutated antigens that were identified to be frequently expressed in non-small cell lung cancer (“NSCLC”). The company's another product BNT211 is an autologous tumor-specific CAR-T cell therapy candidate targeting CLDN6 which is enhanced by a CAR-T cell amplifying RNA cancer vaccine (CARVac)...
